Nuwellis Postpones Q2 Earnings Release, Conference Call
ByAinvest
Wednesday, Aug 6, 2025 8:18 am ET1min read
IBRX--
The postponement comes as Nuwellis continues to navigate its financial reporting process. The company's Q1 2025 earnings release and conference call were held on April 28, 2025. The Q2 2025 earnings release was initially expected to be released on July 15, 2025, but has now been delayed to accommodate the additional time needed for valuations and audit procedures.
Nuwellis has been actively engaged in its financial reporting process, working closely with its auditor to ensure the accuracy and completeness of its financial statements. The company's commitment to transparency and accurate financial reporting is reflected in its decision to delay the earnings release to ensure that all necessary steps are taken to provide investors with a comprehensive and accurate picture of its financial performance.
The postponement of the Q2 earnings release and conference call is a reminder of the importance of thorough and careful financial reporting. Investors and financial professionals should continue to monitor Nuwellis' progress and await the release of its Q2 2025 earnings report.
References:
[1] https://finance.yahoo.com/news/immunitybio-reports-q2-earnings-release-110000675.html
NUWE--
• Nuwellis postpones Q2 earnings release and conference call • Requires additional time for valuations and audit procedures • No disagreements with auditor Baker Tilly US, LLP • New conference call scheduled for August 14, 2025 • To be held at 9:00 AM ET via webcast and phone dial-in • Audio archive available after the call on the Nuwellis website
Nuwellis, Inc. has announced the postponement of its Q2 2025 earnings release and conference call. The company requires additional time for valuations and audit procedures, and there are no disagreements with its auditor, Baker Tilly US, LLP. The new conference call is scheduled for August 14, 2025, at 9:00 AM ET. It will be held via webcast and phone dial-in, and an audio archive will be available after the call on the Nuwellis website.The postponement comes as Nuwellis continues to navigate its financial reporting process. The company's Q1 2025 earnings release and conference call were held on April 28, 2025. The Q2 2025 earnings release was initially expected to be released on July 15, 2025, but has now been delayed to accommodate the additional time needed for valuations and audit procedures.
Nuwellis has been actively engaged in its financial reporting process, working closely with its auditor to ensure the accuracy and completeness of its financial statements. The company's commitment to transparency and accurate financial reporting is reflected in its decision to delay the earnings release to ensure that all necessary steps are taken to provide investors with a comprehensive and accurate picture of its financial performance.
The postponement of the Q2 earnings release and conference call is a reminder of the importance of thorough and careful financial reporting. Investors and financial professionals should continue to monitor Nuwellis' progress and await the release of its Q2 2025 earnings report.
References:
[1] https://finance.yahoo.com/news/immunitybio-reports-q2-earnings-release-110000675.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet